Holen Sie sich die Stockscreener-App
135.56
0.40%
-0.55
Handel nachbörslich:
135.56
Schlusskurs vom Vortag:
$136.11
Offen:
$136.11
24-Stunden-Volumen:
416.66K
Relative Volume:
0.60
Marktkapitalisierung:
$8.72B
Einnahmen:
$74.06M
Nettoeinkommen (Verlust:
$-114.71M
KGV:
-75.15
EPS:
-1.8039
Netto-Cashflow:
$-117.90M
1W Leistung:
+0.96%
1M Leistung:
+11.22%
6M Leistung:
+63.17%
1J Leistung:
+145.80%
1-Tages-Spanne:
$135.43
$139.92
1-Wochen-Bereich:
$131.05
$139.92
52-Wochen-Spanne:
$50.48
$143.29
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
135.56 | 8.75B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics Inc (PTGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Protagonist Therapeutics Inc (PTGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PTGX|Protagonist Therapeutics Inc|Price:136.110|Chg%:+0.680 - TradingKey
Protagonist Therapeutics Inc (PTGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Protagonist Therapeutics, Inc. Revenue Breakdown – NASDAQ:PTGX - TradingView
TradingKey - TradingKey
Protagonist Therapeutics Inc (PTGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) - The Globe and Mail
PTGX Pulls Back: Protagonist Therapeutics Holds Above Support After Modest DeclineDealer Gamma - dars.gov.et
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
PROTAGONIST THERAPEUTICS INC : JEFFERIES RAISES TARGET PRICE TO $172 FROM $121 - Bitget
Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup - ChartMill
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $155 - Moomoo
Protagonist Therapeutics stock hits all-time high at 141.79 USD By Investing.com - Investing.com Australia
Liquidity Mapping Around (PTGX) Price Events - Stock Traders Daily
PROTAGONIST THERAPEUTICS INC : TD COWEN RAISES TARGET PRICE TO $155 FROM $100 - Bitget
Protagonist Therapeutics stock hits all-time high at 141.79 USD - Investing.com
Protagonist Therapeutics (PTGX) Barclays 28th Annual Global Healthcare Conference summary - Quartr
Protagonist Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open - Sahm
Protagonist Therapeutics Jumps 5.7% Amid Sector-Wide Rally - AlphaStreet
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Citizens raises Protagonist Therapeutics price target on Icotyde uptake By Investing.com - Investing.com Canada
Citizens JMP Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Three New Hires Receive Protagonist Options and RSUs Under Inducement Plan - Stock Titan
Protagonist Therapeutics Jumps 5.3% After Barclays Maintains Overweight - AlphaStreet
Protagonist Therapeutics Is Maintained at Overweight by Barclays - Moomoo
PTGX Maintained by Barclays -- Price Target Raised to $151 - GuruFocus
Barclays Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Best Momentum Stocks to Buy for July 13th - Yahoo Finance Singapore
Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Protagonist Therapeutics (PTGX) AGM 2026 Summary - Quartr
Protagonist Therapeutics (PTGX) Investor Update Summary - Quartr
Protagonist Therapeutics Inc. (PTGX) Q1 2026 Earnings: Surprise Profitability Defies Estimates, Yet Shares SlideEPS Consistency Score - dars.gov.et
Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review - Yahoo Finance
Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued - Yahoo Finance
New Strong Buy Stocks for July 9th - Yahoo Finance
Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest - simplywall.st
Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review FocusHas The Bull Case Changed? - Yahoo Finance
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains? - Yahoo Finance
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX) - The Globe and Mail
PTGX climbs as target hike adds to late-stage pipeline optimism - Quiver Quantitative
PTGX Stock Grinds Higher As Pipeline Catalysts Build - StocksToTrade
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com - Investing.com India
Protagonist Therapeutics updates its clinical pipeline. PTGX focuses on peptide-based therapies - ad-hoc-news.de
Protagonist Therapeutics Jumps 5.2% Amid Sector-Wide Rally - AlphaStreet
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally? - TradingView
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $145 - Moomoo
PTGX Maintained by Truist Securities -- Price Target Raised to $145.00 - GuruFocus
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):